What is a "food-derived bioactive technology" and a "functional food"?
It is becoming increasingly accepted by the scientific community that there are links between specific food groups and their capacity to help reduce the risk of certain diseases. For example, some compounds specifically found in broccoli have been shown to reduce the risk of some cancers. Consuming the actual food may be insufficient to maximise the health benefit due to a number of factors including: the quantity of the food that would need to be consumed; the frequency with which it would need to be consumed; and the way in which the food is prepared prior to consumption.

These health-promoting compounds can be extracted from the food source (called a food-derived bioactive technology) and reintroduced into consumer-friendly lifestyle products which are proven to maintain health (a functional food). Therefore, instead of eating four large servings of broccoli per week, the same benefit may be technically delivered via a 250ml orange juice drink containing the bioactive if consumed once per week.

How is Provexis differentiated from other companies in the market?
Provexis is an evidence-based business which means that we only develop food-derived bioactive technologies and functional food products that have been scientifically proven to deliver a health benefit. This is a different approach from those that promote functional food products in a more generic way with less scientific evidence. We believe that functional food products with strong scientific proof carrying health claims and endorsements will endure and prosper as this rapidly growing market matures.

Provexis is also differentiated with regard to our speed-to-market credentials and the fact that we can create shareholder value via a combination of technology licensing and own brand development.

What food-derived bioactive technologies are being developed by Provexis?
Provexis has developed Fruitflow, a patented extract from tomato that has been proven to inhibit blood platelet aggregation, thereby reducing the risk of thrombosis. A thrombosis is an aberrant blood clot that can lead to heart attack and stroke. Provexis has integrated Fruitflow into a fruit juice beverage called Sirco. When launched - initially in the United Kingdom - it will be the first functional food carrying the claim Helps maintain a healthy heart and benefit circulation with a measurable benefit within hours of consumption.

Provexis is developing a proprietary extract from a special breed of broccoli (non-GMO) which is enriched in compounds known to reduce the risk of specific cancers. Provexis intends to use this food-derived bioactive to underpin a new range of functional beverages with scientifically proven protective properties.

In addition, Provexis is developing a patented extract from plantain with a view to developing a novel medical food for the dietary management of Inflammatory Bowel Disease, specifically Crohns Disease in the first instance.

PROVEXIS PLC
("Provexis" or the "Company")

Provexis and HEART UK enter product endorsement agreement

Provexis, the nutraceutical company that develops scientifically proven
functional and medical foods, is delighted to announce their entry into an
initial three-year agreement with the registered heart health charity, HEART UK,
which will see formal approval of the Company's lead product, the fruit juice
drink Sirco(TM). In addition the two organisations will collaborate in research
and educational activities designed to increase awareness of family heart
health issues amongst the public.

Sirco(TM), carrying the HEART UK logo, will initially be available in two
flavours and the Company is currently planning, with major retailers, a national
UK launch. The Sirco(TM) packaging will show that the product "Helps to maintain
a healthy heart and benefits the circulation."

Sirco(TM) contains the patented natural fruit extract called Fruitflow(TM).
Fruitflow(TM) was discovered at the Rowett Research Institute in 1998 and since
2000 has been developed and clinically tested in human trials by Provexis.

Fruitflow(TM) contains a range of tasteless tomato-derived natural compounds
which have been proven to inhibit platelet aggregation, a part of the blood-
clotting process which can cause heart attack and stroke.

According to the British Heart Foundation, heart and circulatory disease is the
UK's biggest killer.

Sirco(TM) is being launched into a new, emerging category in the UK:
"heart-healthy" functional juices. This category first emerged in the US in the
last two years, with rapid growth to 2004 sales of $100.1m, according to
Information Resources Inc. data.

Dr Stephen Franklin, Chief Executive Officer of Provexis, said: "The approval
granted by HEART UK is excellent news, and we look forward to working together
in a proactive manner to promote heart health. Our strategy is to differentiate
ourselves in the functional food industry by investing in R&D and developing
products that taste great, deliver proven health benefits, and carry credible
health claims supported by strong scientific proof."

Michael Livingston, the Director of HEART UK said: "The Charity is delighted
to be embarking on a long-term partnership with Provexis plc to help people take
proactive steps to reduce their risk of heart disease."


Ends


For further information please contact:

Provexis plc
Dr Stephen Franklin, CEO 07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232


Notes to Editors

Provexis develops scientifically proven functional and medical foods. Functional
foods are foods such as Benecol and Flora pro.activ that contain physiologically
active food components and provide health benefits beyond basic nutrition. In
June 2005 the Company joined AIM via a reverse takeover by Nutrinnovator.
Nutrinnovator came into operation in February 2003 and launched the Altu
nutrition bar, floated on AIM in June 2004 and brings with it a technology
pipeline as well as marketing, selling and business development skills.

Provexis was formed in December 1999 by the life-science subsidiary of the
venture-management company, ANGLE plc. In January 2000, Provexis entered into a
new technology option agreement with Rowett Research Services Ltd. (RRS), the
commercial subsidiary of the Aberdeen based Rowett Institute, and this option
was exercised in November 2001. Provexis' agreements with RRS have provided it
with the intellectual property rights pertaining to its lead product, Fruitflow.
Provexis continues to have strong links with the Rowett Institute, which
provides the company with R&D facilities, human trials and, potentially, new
technologies.

HEART UK is a national charity of patients and their families, supporting
research and helping to increase awareness and understanding of the importance
of Heart Health and how to maintain a healthy cardiovascular system. HEART UK
works with patients and their families and combines the rich skills of research
scientists, the caring knowledgeable attention of doctors, nurses and
dietitians, in order to support all those at risk of cardiovascular disease.

Product Overview

The company has an initial pipeline of four products in development:

* Fruitflow(TM) - a proprietary tomato extract proven to reduce platelet
aggregation which reduces the risk of thrombosis, a major cause of heart
attack and stroke
* Plantain extract - for digestive health and management of inflammatory
bowel disease
* Superbroccoli - broccoli based extract for the reduction of risk of
specific cancers
* Omega III oil technology - for heart-health and cognitive benefits

The Fruitflow(TM) intellectual property rights are broad and well protected, and
the product has been granted patent in Europe and Australia, and has a patent
grant pending in the US.

Hi All

Thought I would start this thread to get the ball rolling on this company, if you are in let us know what you think, if you are thinking of getting in tell us why, and if you think its a dog a would'nt touch it with a barge pole, why not?

Look forward to hearing your veiws, good or bad.

Regards Doh

Hi Doh, ive just started looking in to this one, ,shares mag featured it a few weeks back,, looks interesting, they have a website with lots of info , i'll be back...Cheers JB...

You may have already looked at this , but just in case it's www.provexis.com, check it out..

i used to have angle because of pxs. bought pxs a few weeks ago after seeing it getting a mention in shares mag. i think the agm statement has kicked this one into life. buy now and wait till january.

Provexis plc

AGM STATEMENT


Dawson Buck, Chairman of Provexis plc, will make the following statement at
today's Annual General Meeting ('AGM'):

'Provexis plc was admitted to trading on AIM exactly two months ago. This was
the coming together of two businesses, Provexis Limited and Nutrinnovator
Holdings plc, with the shared vision of creating a company which is now uniquely
differentiated in the functional food market.

Subsequently, I am delighted to report that the integration has gone extremely
well and the new team has a clear, shared energy and commitment to the future
success of Provexis plc.

Our lead product, SircoTM, is a fruit juice drink that contains a patented
bioactive extract from tomatoes (called FruitflowTM). It has been proven in
human trials to inhibit blood platelet aggregation and thereby reduce the risk
of thrombosis, the primary cause of heart attack and stroke. SircoTM, which
carries a health claim, is uniquely positioned in the heart health category due
to its function and the immediacy of the benefit.

Earlier this month we announced a three-year agreement with the registered heart
health charity, H-E-A-R-T UK, for SircoTM, which provides us with formal
approval and endorsement of the product.

Due to the high level of interest from a number of the major UK supermarkets and
other key high street retailers, we are now planning a much larger distribution
base at launch, supported by a nationwide marketing campaign in early 2006.

Both the supermarkets and the retailers have indicated that maximum impact will
be made by a launch in the post-Christmas period, when health and wellbeing is
at its highest on the consumer's personal agenda. We will therefore be launching
SircoTM in January 2006.

Whilst the current focus is working towards the launch of SircoTM the R&D
pipeline, in conjunction with our technology partners, continues to progress.
This includes the functional fruit juice beverage which will contain a
proprietary extract from broccoli proven to reduce the risk of specific cancers
and the medical food for the dietary management of Crohn's Disease. The Board
continues to monitor the Altu food bar and is considering its future strategy in
relation to this product.

Provexis plc has made a positive start since admission to AIM in June and the
Company is now gearing up to the launch of SircoTM in January 2006. I look
forward to reporting further progress in due course.'

Cheers bosley..

Looks wildly speculative to me, but if the alternative is to eat pounds of tomatoes and broccoli every day....

Exactly, partridge you would need to eat 10 bushes of broccoli and 487 tomatos, twice a day , so if your not interested in the shares, at least drink the product !!

jimmy, when angle spoke about the product there was mention of the airlines being interested, as the tomato extract works similar to asprin in thinning the blood so it would be useful in combatting deep vein thrombosis. i haven't seen anything about that since, but it certainly makes sense for the long haul airlines to offer such a drink.
partridge, yes, very speculative and pxs is pretty much a one horse company at the moment, so if sirco doesn't happen it will collapse on it's arse. but, if it does happen............

bos i know ,,they are going for the airports as well ,,have you been on the website? i'm not in as yet ,, but i'm lurking..

Hi All

Glad there is some interest out there, I have been in this for a couple of days now, dipped a toe at 7p and stuck both legs in 7.5p , I must admit I wasn't expecting it to rise quite so quickly. Its not to surprising though when you look at the product.

partridge: I wouldn't have said it was wildly speculative, I think the fact they have independent clinical trials to back up their claims and the fact they have the backing of a heart charity may just promote this to speculative. The only reason I think you could possible keep this in the speculative category is because the product is not on the shelves yet.

bosley: excellent advise, however I think I might wait a bit longer I want to see how they intend to spend the 2.5mil advertising budget.
jimmy b: Don't lurk to long, hope to see you on board soon, however if you turn up something you don't like feel free to share it with us.

Best of luck to all,
Regards Doh

doh. that's probably the best thing about pxs , that it's gone past trial stage and is a product waiting to be launched. i got in at 5.5p but, like yourself, was surprised at the sudden movement. if pxs is successful then agl would also be a good buy as it still owns 24/25%.
jimmyb, i didn't think about the airports but it makes sense. (take a butchers at icu, jam tomorrow but could be nice)

pxs having a good day today , as is icu . good feature in shares mag yesterday about the boss of icu. it's about time shares mag had pxs as a play of the week. they have already done a couple of features on it.

A good day indeed bosley. Many more please. LOL

another kick up for pxs. again this wasnt flagged up by the news ticker!!

"Provexis PLC
12 September 2005


PROVEXIS PLC
('Provexis' or the 'Company')

COLLABORATION AGREEMENT FOR CROHN'S DISEASE TECHNOLOGY

Exercise of right to assign intellectual property from University of Liverpool


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has entered into
a collaboration agreement with a leading clinical nutrition company ('the
Company').

Provexis is currently developing a proprietary bioactive extract from the
Plantain (part of the banana family) which is designed to extend remission in
patients suffering from Inflammatory Bowel Disease (IBD). IBD has two forms,
Crohn's Disease and Ulcerative Colitis, both are chronic inflammatory diseases
of the digestive tract which, combined, affect approximately 1 in 400 in the
western world countries.

Under the terms of the collaboration agreement, Provexis and the Company will
develop a medical food product incorporating this bioactive extract. It is
intended that the food product will enter clinical trials in 2006 on patients
suffering from Crohn's disease. Crohn's Disease is currently incurable with the
primary goals of treatment being control of the inflammation, the relief of
symptoms, addressing nutritional deficiencies and the extension of remission
time.

The Company will be responsible for the formulation, manufacture and packaging
of the medical food product to be used in the full clinical trial and will have
the option of securing an exclusive negotiation period after the trial. The
negotiation period would give the Company the rights to be the first company to
pursue the manufacturing and distribution rights for the product. However,
Provexis is not obliged to enter into an agreement with the Company for these
rights and furthermore, all intellectual property, including the industrial
formulation of the medical food product, is wholly-owned by Provexis.

In addition, following successful pre-clinical studies on this medical food
treatment by the University of Liverpool and Provexis, Provexis has exercised
its right to the assignment of the intellectual property from the University of
Liverpool to a new Provexis subsidiary in which the University will be a
minority shareholder.

The specific components in Plantain with this therapeutic potential were
discovered by Professor Jon Rhodes, based in the Department of Medicine at the
University of Liverpool and an Honorary Consultant Gastroenterologist at the
Royal Liverpool University Hospital.

Dr Stephen Franklin, CEO of Provexis, commented: 'This is another significant
milestone in the development of Provexis. This collaboration is an important
validation of the strength of the Provexis technology pipeline.'


Ends


For further information please contact:

Provexis plc
Dr Stephen Franklin, CEO 07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232


Notes to Editors

Provexis develops scientifically proven functional and medical foods. Functional
foods are foods such as Benecol and Flora pro.activ that contain physiologically
active food components and provide health benefits beyond basic nutrition.
Medical foods are administered to patients by a physician for the dietary
management of specific diseases.

In June 2005 the Company joined AIM via a reverse takeover by Nutrinnovator.
Nutrinnovator brings with it a technology pipeline as well as marketing, selling
and business development skills.

Provexis was formed in December 1999 by the life-science subsidiary of the
venture-management company, ANGLE plc. In January 2000, Provexis entered into a
new technology option agreement with Rowett Research Services Ltd. (RRS), the
commercial subsidiary of the Aberdeen based Rowett Institute, and this option
was exercised in November 2001. Provexis' agreements with RRS have provided it
with the intellectual property rights pertaining to its lead product, Fruitflow.
Provexis continues to have strong links with the Rowett Institute, which
provides the company with R&D facilities, human trials and, potentially, new
technologies.


IBD - Technical

Researchers at the University of Liverpool have recognised that IBD may
represent an altered response to normal intestinal microbes In particular, they
believe there is a possibility that apparently non-pathogenic 'harmless '
bacteria can cause inflammation if they penetrate the intestinal mucus and
associate themselves with the lining cells of the intestine.

The researchers have characterised the adherence of Inflammatory Bowel Disease
related bacteria to carbohydrate structures on the lining of the intestine and
found that the adhesion of such bacteria to cell surfaces can be blocked by
some, but not all, complex carbohydrates. In particular, they found that
specific types of soluble fibre, extracted from Plantain, were particularly
effective for preventing bacterial adhesion and accordingly may have efficacy
for preventing or treating IBD. They believe that the soluble fibres may either
mimic or compete with bacterial receptors, thus preventing bacterial recruitment
and subsequent inflammation.

This discovery has led Provexis to believe that a Plantain--based formulation
(as developed by chemists at Provexis and tested at the University of Liverpool)
could underpin a new medical food treatment for extending remission time in
patients with IBD.

The medical food product is anticipated to enter a two-site clinical trial on
patients with Crohn's Disease in Summer 2006.



This information is provided by RNS
The company news service from the London Stock Exchange

just seen this on the psg thread. hope sd doesn't mind. taken from a post from feb 2005.

"Peter Brabeck, head of Nestle and one of the most influential
people in the food industry, was interviewed in yesterdays Financial
Times:-

"It is my conviction that the next value creation, and it will be huge,
is going to be nutritional aspects. That is what allows you to ask 40%
more for your products".

The article continued that foods with medical benefits, otherwise known
as functional foods or nutraceuticals are expected to be the big source of
growth for the next 15 to 20 years. "

all gone a bit quiet and the sp has dropped a touch. not really much going to happen until january , i think.

looks like pxs have decided to ditch altu. makes sense as it was loss making.

Provexis PLC
05 October 2005


PROVEXIS PLC

Disposal of Altu

Provexis plc ('Provexis' or the 'Company') AIM: PXS.L, announces the sale of its
Altu food business to Go Lower Limited for a cash consideration of 75,000 which
will be used for working capital purposes.

As stated at the AGM, the Board has been closely monitoring the performance of
Altu. The brand has recently extended its distribution, via a new pack format,
in two multiple grocers, and continues to enjoy national distribution in High
Street and Major Multiple Grocers. However, following a strategic review, the
Board has concluded that, in order to focus on the core activity of functional
foods, a disposal of the Altu business is in the best interests of the Company
and shareholders.

For the year ended 31 March 2005, the Altu business was loss-making, after
direct overheads on turnover of 298,000 and in the year to date has continued
to be loss-making. The disposal therefore will have a cash positive effect on
Provexis' business going forward.

Commenting, Dr Stephen Franklin, CEO said:

'Provexis will now be able to focus its resources and management time on its
core business: the development of novel, patented, food bioactives with
scientifically-proven health benefits. These will be commercialised via a
combination of licensing and own-brand functional foods.'

3 November 2005

PROVEXIS PLC
('Provexis' or the 'Company')


US PATENT AWARDED COVERING FRUITFLOW TECHNOLOGY


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has received a patent grant from
the United States Patent Office covering its FruitflowTM technology.

The FruitflowTM technology covered by this patent was discovered at the Rowett
Research Institute in 1998 and has been developed and clinically tested by
Provexis since 2000. FruitflowTM contains a bioactive extract from tomatoes
which has been proven in human trials to inhibit blood platelet aggregation and
thereby reduce the risk of thrombosis, a primary cause of heart attack and
stroke. The technology already has patent protection in Europe, granted in July
2003, and in Australia, granted in August 2004. It is also anticipated that
patent protection will be granted in Japan, Mexico and Canada in the near
future.

Provexis will be launching the FruitflowTM technology in its lead product, the
fruit juice drink SircoTM, in January 2006 in the UK. SircoTM has been approved
by HEART UK and will carry the claim 'helps to maintain a healthy heart and
benefits the circulation'. SircoTM is differentiated from existing cholesterol
management products in that the benefit is associated with blood thinning and is
effective from the first serving. The launch will be targeting a new, emerging
category in the functional food market in the UK: heart-healthy functional
juices. The market for heart-healthy foods worldwide is expected to reach US$4.6
billion of sales by the end of 2005.

Dr Stephen Franklin, Chief Executive Officer of Provexis, said: 'We are
delighted to have been granted the US patent for our FruitflowTM technology. We
now have patent protection in our two largest target markets, the United States
and Europe. This is a critical development in terms of our licensing ambitions
and it means that we can start to make significant in-roads into the US
functional food market, which is expected to reach US$34 billion of sales by
2010.'


this is fantastic news for pxs!!!

wheres this one going fruit flow released to market january ,going to get some haVe a taste .they haVe had 2 jumps off 5p will they brake this range to find 10p and aboVe ,they were 60p without there patent or product tomarket .i hold 50k shares at 6.4p ,thinking to double up on next dip haVe a good feeling about these ,

more news today.

Provexis PLC
07 November 2005



7 November 2005



PROVEXIS PLC
('Provexis' or the 'Company')


Provexis plc is awarded Research Grant for Crohn's Disease Technology from North
West Development Agency


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has been awarded
a research grant for its Crohn's disease technology from the North West
Development Agency. The grant is for 180,000 and will assist the funding of the
Company's development of its novel, medical food for the treatment and dietary
management of inflammatory bowel disease (IBD).

Provexis is currently developing a proprietary bioactive extract from plantain
(part of the banana family) which is designed to extend remission in patients
suffering from IBD, which exists in two forms - Crohn's disease and ulcerative
colitis. Collectively, both forms of the disease affect approximately 1 in 400
in the western world. According to Decision Resources (2004), for Crohn's
disease alone, the therapeutic market across the seven major countries in the
world was estimated at 1bn in 2003 with new technologies expected to be the
driver behind significant growth.

The proposed medical food contains a patented natural source of soluble fibre
extracted from the plantain. If successful, it will be the first medical food
which involves treatment of the actual inflammation associated with the disease,
unlike existing medical food treatments which only address nutrient
insufficiencies and imbalances in IBD sufferers.

Provexis had previously secured financial support for this project from the DTI
in 2004 with a 45,000 DTI SMART Feasibility Award.

The award from the North West Development Agency was won following a competitive
pitch which involved rigorous analysis of the Company's technology, intellectual
property and commercial capability by a team of independent referees.

Commenting on the grant, Provexis' Chief Executive, Dr Stephen Franklin, said:
'We are delighted to receive this substantial grant from the North West
Development Agency. Given the strength of the competition in bidding for this
award, it is a clear testament to the quality of the technology we are
developing, the robustness of the intellectual property and the scale of the
commercial opportunity. Crohn's Disease remains an area of significant unmet
clinical need in a therapeutic market that now exceeds 1bn. This grant enables
us to extend the scale of the clinical trial which commences next year.'

results

Provexis PLC
16 December 2005




PROVEXIS PLC
('Provexis' or the 'Company')

UK Launch of Sirco(TM)

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to confirm the launch of its
Sirco(TM) heart health juice drink in the UK in January 2006.

The Company has so far secured an initial distribution base with two of the five
largest supermarket retailers in the UK, which for reasons of commercial
confidentiality cannot be named at present. Both retailers will distribute
Sirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)
will be initially available in premier stores which represent, by weighted
distribution, approximately 35 per cent. of their total UK distribution base.
Within the second supermarket chain, Sirco(TM) will be initially available, by
weighted distribution, across 70 per cent. of their total UK distribution base.
Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,
Apple & Blueberry and Orange, and the drink will be located in the chilled fruit
juice section.

The Company is in on-going discussions with a number of other retailers and
hopes to make further distribution announcements in 2006. In addition to the one
litre packs, the Company is also developing a 250ml bottle of Sirco(TM) for
distribution to retailers in mid 2006. This bottle will have an extended shelf
life and is intended to widen the distribution base to include independent
chemists, convenience stores and food service industry channels such as health,
education and travel outlets.

Sirco(TM) is the first heart health product to contain the patented
Fruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order to
help regular 'healthy' consumers reduce the risk of heart attack and stroke. The
natural bioactive works by reducing blood platelet aggregation ('thinning the
blood'), a significant contributing factor to a thrombosis (internal blood
clot). Sirco(TM) carries the health claim 'Helps to Maintain a Healthy Heart and
Benefits Circulation' and is approved by the leading heart health charity, HEART
UK.

Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said:

'This marks a significant milestone for Provexis and we are delighted that we
have secured distribution with two of the largest UK supermarkets. Both
retailers are ideal outlets in terms of the demographics and target market for
this product. We will be investing in media advertising as well as in-store
activity to ensure we maximise this substantial opportunity.

We look forward to growing the retailer base for Sirco(TM) throughout 2006,
whilst in parallel securing licensing arrangements with major international food
partners to integrate the FruitFlow(TM) technology into new food products in
global markets.'



good news!!

yes good news on the shelVes january and adVerts planed to get attention ,bought back in after takeing profit about month ago, in lower aVarage 6.1 better than last time got it right for this one. we should see more gains next week now supermarkets are onboard.

up 11% would like to know what is posible income from fruit flow ,these should keep on riseing lot of Volume today.

cellby
15m sells yet your up 11% ?

driVer not sure that was all selling ,may haVe been sum orders filled from friday or first thing today . it was nearly certain to go up today with news from friday product on shelVes 2 super market chains and more to come ,its out of the deVelopment pan into the sales fire.could be some big profit takeing if we hit 8p including me.may be a return tomorrow about all these million of shares moVeing home.

x-trades thread

i know today's sells are not x trades, but it may be the same explanation for the rise.

STRONG BUY

who from ,sold half of mine yesterday 15% profit on day trade ,thought might get them back on the drop ,didnot get there 6.4 my buy back may not see it.

From me - nice strength shown today intra-day, relatively low sell volumes today, most people in for the launch. Think this will rise for the last 2 days of the week and possibly form a new high.

From the company secretary.

Sirco will be available in Sainsburys from the second week in January in the chilled juice section, and will be available in Waitrose stores from 25th January. Unfortunately, at this stage I am not able to tell you which stores, until the retailers confirm this information with us.

Provexis PLC
09 January 2006


9 January 2006

PROVEXIS PLC
('Provexis' or the 'Company')

Further Major Distribution Agreement for SircoTM

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces a further distribution agreement with a
market leading supermarket chain for its SircoTM heart health juice drink.

From February 2006, SircoTM Blueberry & Apple variety will be stocked in
approximately 200 of this supermarket's key premier stores bringing the total UK
distribution base for SircoTM to over 500 stores by the end of February 2006.

Further to the Company's announcement released on 16 December 2005, SircoTM is
now available in 211 Sainsbury's stores and is expected to be available in 100
stores of the second multiple supermarket chain from 23 January 2006.

SircoTM is the first heart health product to contain the patented FruitflowTM
technology. FruitflowTM was developed by Provexis in order to help regular
'healthy' consumers reduce the risk of heart attack and stroke. The natural
bioactive works by reducing blood platelet aggregation ('thinning the blood'),
a significant contributing factor to a thrombosis (internal blood clot). SircoTM
carries the health claim 'Helps to Maintain a Healthy Heart and Benefits
Circulation' and is approved by the leading heart health charity, HEART UK.

Commenting on the expanded distribution, Dr Stephen Franklin, CEO of Provexis,
said:

'We are delighted to have secured a listing with a third major retailer. The
distribution base of SircoTM is expanding on schedule and will be sufficiently
established to maximise the nationwide, multimedia, advertising campaign which
will run throughout the Spring and early Summer'.

For further information please contact:

Provexis plc
Dr Stephen Franklin 020 8392 6631

Bell Pottinger Corporate & Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232

looks like everything is going to plan.

Provexis PLC
17 January 2006


PROVEXIS PLC ('the Company')

17 January 2006

DIRECTORS' DEALINGS

On 16 January 2006, the Board of Provexis plc approved the grant to Directors of
options over ordinary shares in the Company under the Company's 2005 Share
Option Scheme, exercisable at 8.62p per share, any time between 3 and 10 years
of the date of grant, as follows:

Director Options granted Total Options held following Grant

Stewart Slade 2,088,167 2,088,167

The options are exercisable between 3 and 10 years from grant.

so far , so good. pxs has been nicely moving in the right direction. the product is now out on supermarket shelves. i would imagine that the company will soon be giving an indication of how sales are going.

it just gets better and better.

"Provexis PLC
23 January 2006


PROVEXIS PLC
('Provexis' or the 'Company')

Significant Increase in Number of Distribution Outlets for SircoTM

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces a significant increase in the number of
distribution outlets for its SircoTM heart health juice drink, under the terms
of its most recent distribution agreement with a market leading supermarket
chain.

Further to the Company's announcement of 9 January 2006 detailing its third
distribution agreement, SircoTM will now be available in 550 of this retailer's
stores from 30 January 2006, representing an increase of 350 outlets. Sirco is
now available in 211 Sainsbury's stores and will be available in 123 Waitrose
stores from 23 January 2006. This will bring the total UK distribution base for
Sirco to 884 stores by the end of January 2006.

SircoTM is the first heart health product to contain the patented FruitflowTM
technology. FruitflowTM was developed by Provexis in order to help regular
'healthy' consumers reduce the risk of heart attack and stroke. The natural
bioactive works by reducing blood platelet aggregation ('thinning the blood'), a
significant contributing factor to a thrombosis (internal blood clot). SircoTM
carries the health claim 'Helps to Maintain a Healthy Heart and Benefits
Circulation' and is approved by the leading heart health charity, HEART UK.

Commenting on the expanded distribution, Dr Stephen Franklin, CEO of Provexis,
said:

'We are delighted to have received this substantial increased commitment from
the third major retailer prior to the date of its planned launch. Our focused
media campaign to consumers is scheduled to commence on 21 January 2006 and our
sales support activities have been in effect since 10 January' "

can't believe the lack of interest in this.

check the AFN board. there are more followers in PXS there.

ecomkid, there were some on here , but they seem to have disappeared just as things are getting interesting.

unreal!!!!!!! come on baby!!!

bos
I have this on my watch list it's doing well

driver, just a little ;)

still no interest ? as long as the drinks sell there really isn't too much downside to this. there's still a raft of outlets for pxs to target. that could mean a steady flow of news about new outlets and then hopefully some good sales figures announcements.

lovely rise here ,too :)

Hi. Have been accumulating for a while. Big potential here IMO. V little downside for health products at the moment + some big distribution deals in the pipeline apparently.

down today. no reason why that i can see, but , then again, it can't really go up everyday :)

Fell on v low volume. ??

No interest here!!

I see from the provexis website that the products will be selling in 884 outlets in the UK by end of jan '06. EOY is 31.03.06 so the figures should be positive. We shall see. (.6mfor 04/5)

From 23.01.06

Provexis, the nutraceutical company that develops scientifically-proven functional and medical foods, announces a significant increase in the number of distribution outlets for its Sirco heart health juice drink, under the terms of its most recent distribution agreement with a market leading supermarket chain.

johnny, that's already been posted. not much to do or say for the time being except wait for some figures or news about new distribution agreements.

Bosley Hi.

Am surprised at the lack of interest. As far as I can see there are no threads on advfn or fyb for this co.

The only downside AFAICS is if the product is so gross that it doesn't sell. But I can't see that as likely.

Has anyone found Sirco instore yet?

johnny the fox
advfn thread
www.advfn.com/cmn/fbb/thread.php3?id=9310489

yes.it's in lot's of stores here in the notts area.. my fridge has a good supply, it tastes good, and if it help me to avoid having a stroke..i'll keep drinking it. cheap at half the price..i can see half the county on it ,if they know what's good for them.that can only mean one thing for the share price..cheer's...

Hi, folk. Some old pals here which is encouraging. Having a look at recommendation of Bos who made me a killing on SEO. This one could avoid the killing! Can't find any projections of sales value. If there are 800+ stores selling it how many each. Presumably margin is not that great, given the power of the s-m's.

Eric

Be wary of competition.

Asda have "innocent" on half price promotion right now, i'll assume that is to get
people to try their drinks as there cannot be that many people around prepared
to pay 3 quid for a carton of juice no matter how nice, natutral and healthy it is.

Look at the health milk drinks, Actimel started the advertising blitz and now there's
loads of these bacteria drinks competing with each other.

So Provexis might have a great drink but there will be so many others lining up to
compete with them so if the shares have a good run it might be sensible to bank
profits, i would'nt chase the share price as the market cap is already quite high.

ravey davey gravy, (great name btw and many congratulations on champinvest), it is another health drink although this one is heart healthy, thinning the blood in the same way as aspirin. pxs also hold the ip for the main ingredient, some tomato extract. the potential is there as a health drink , but also , i would like to see pxs try to get the airlines interested as it could work combatting deep vein thrombosis. it's a gamble at the moment until some sales figures are in. thanks for your thoughts, much appreciated.

eric, got your email. cheers.

Thanks bosley.

Yes the drink sounds a lot more promising than squashing a load of fruit
into a carton.

Good luck with this stock.

ravey davey gravy: did you win it? great performance anyhow.

So what's a mere health food drink in comparison to an oil gusher? Somewhat easier to set up in this market than build an oil rig. My early reaction is that there is a lot of groundwork behind this one plus endorsement by HEART UK; also some interesting developments in the 'pipeline'.

Have put my pocket where my mouth is and bought in this morning at 12p. You guys have healthy profits already but I suspect we are still in the early stages of positive newsflow; this is a natural for Mail readers. Three major supermarkets on board without s significant movement in sp.

Eric

bosley - you should fly easyJet. You only get DVT with them if you pay extra for it. lol!

I'm sticking woth PSG on the nutraceuticals front for now. Price is in the dildrums and a good time to accumulate. I believe them to be the SEO of the pharma's with their phosphorylation techniques' extremely wide applications to make exisiting drugs and vitamins water soluble for first time - e.g. morphine (transdermal delivery) and vitamin E (also good for the ticker) - sorry off thread, but interesting to compare with PXS.

sd

"Peter Brabeck, head of Nestle and one of the most influential
people in the food industry, was interviewed in yesterdays Financial
Times:-

"It is my conviction that the next value creation, and it will be huge,
is going to be nutritional aspects. That is what allows you to ask 40%
more for your products".

The article continued that foods with medical benefits, otherwise known
as functional foods or nutraceuticals are expected to be the big source of
growth for the next 15 to 20 years. "

sd, i nicked that from your psg thread a while ago. hope you don't mind but it seemed apt and could reassure eric that there is a resonable margin for pxs. but, until pxs start putting out some figures it's all guesswork really.

Nice one bos. Been put on aspirin to thin the blood but still haven't found Serco; not in our local Waitrose; will check Sainsbury tomorrow.

I liked sd's dildrums - a sort of doggy diddums doldrums! Now, sd, its not a case of either/or but of both/and. What we need is an sd-type analysis of the potential revenue/profit. Think I'll visit the web-site and try to sniff it out for myself.

Eric

ewrobson if you go on to sirco website it will tell you where you'r nearest store is .if i remember, they e mailed it to me.

FYI - a "dildrum" is something you can play with in private when life is dull!

sd The mind boggles, even bogdrums! Now life is not dull with PXS. It opens up fantasies, not of nubile young ladies like ASC, but of soaring bank balances whilst the population gains longevity. But its difficult sussing what the cap should be wothout any numbers. I just have the gut feel that this will go reasonably quickly to 100m. Impressed by the people with a lovely Lucozade person lading the marketing.

Eric

Sirco has just appeared in our local tesco's (Weston Favel, Northampton) Have yet to checkout the other stores in the area but doubt if the others are not stocking as well. There does not appear to be any specific promotion but there are a few gaps on the shelves.

Looking good.

tesco too? what happened to the 2.5 million they were going to spend on the advertising and promotion campaign. not seen nuffink, yet!!!!

Perhaps the promotion will start when all the participating stores are stocked up?

our local tesco in hucknall, notts was sold out on sat; morrning..look's good to me.. hope they can keep up with production,so we can keep up with the share price !!!!

absolutely fantastic news.

Provexis PLC
09 March 2006


PROVEXIS PLC

('Provexis' or the 'Company')

FruitflowTM has GRAS status affirmed in the United States

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that an independent Expert Panel in the
United States has affirmed FruitflowTM to be Generally Recognised as Safe
('GRAS'), paving the way for products containing FruitflowTM to be marketed in
the United States and Canada.

The Expert Panel agreed that the components of FruitflowTM have a long history
of consumption as part of the normal diet and would be consumed at levels that
are comparable to those that are possible from the consumption of other
tomato-based food products. Furthermore, clinical studies have demonstrated that
FruitflowTM is without adverse effects and well-tolerated.

In the United Kingdom, SircoTM heart health juice drink is the first heart
health product to contain the patented FruitflowTM technology. FruitflowTM works
by reducing blood platelet aggregation ('thinning the blood'), a significant
contributing factor to a thrombosis (internal blood clot) which can lead to
heart attack or stroke. SircoTM, which was launched in the UK in January 2006,
is currently available in selected Tesco, Sainsbury and Waitrose stores.

The GRAS affirmation of FruitflowTM is a significant development for Provexis as
it continues to implement its strategy of commercialising FruitflowTM in the
United States by securing licensing arrangements with global food and drink
corporations. A Mintel report published in August 2005 estimated the market for
heart healthy products in the US was worth $18.7bn and this market is forecast
to grow by 16% by 2010.

Commenting on the news, Dr Stephen Franklin, CEO of Provexis, said:

'We are delighted that FruitFlowTM has been affirmed GRAS as this represents the
essential precursor to unlocking the substantial commercial opportunities
available in North America. With our existing clearance in Europe, we now have
access to our two primary target markets which we intend to realise via our
licensing strategy.'

Another step forward. Huge market in states & canada. Great news.

jtf

been watching and reading for a while and bought in this morning on news...should have known better given the quality of the posters here and bought in earlier but....



GN

Global, Hi. Better late than never. Topped up myself today. Still time to accumulate imho.

Good luck

jtf

http://www.fruitflow.info/

Some interesting info here regarding product & promotion.

jtf

Thanks, bos: fuller quote than on the AFX. Still haven't seen any financial data. Happy its a winner and have an exploratory investment. Just found out from blueindex that they are prepared to cover with CFDs.

Eric

"A Mintel report published in August 2005 estimated the market for
heart healthy products in the US was worth $18.7bn and this market is forecast
to grow by 16% by 2010."

i think that sentence on its own is enough to give you palpitations !!!! it is really difficult to find a downside to this share , as long as the product actually sells.
opposing views appreciated just to stop us rampers getting carried away :)

did anyone else see the news of reports in the last week associated with britvics decline about the rapid change in eating habits? including huge rises in proboitic sales etc in the Uk, decline in sales of readymeals, increase in fruit and veg sales...

all points to a consumer change which is happy with enhanced food stuffs and healthier eating.

GN

Not in but looking good PXS has been promoted to Drivers Tips.

thanks for the product placement.....

Bos, have been trying to find a downside here but yet to find one. The packaging certainly looks appealing/attractive. That's usually the main initial selling point but it's the repeat sales that will really boost the figures. I don't know what it tastes like (have to get down to my local Tesco) but if it tastes as good as it looks?
JTF

http://www.sircoheart.com/

http://www.fruitflow.info/

cheers , jtf.

What is the unit price? Noticed earlier release statement about larger container being on market by mid year. How many is each store stocking and can we deduce the sales volume? Anything else to help with projections re Sirco sales values. Agree bos re the huge size of the US market in particular. Happy to be in, even in a small way.

2.19 for a carton = 4 x 250ml portions.
Most stores seem to stock about 12 cartons at a time.
Tesco only carrying blueberry and apple.
Reports back from investors state product selling well but will need to wait for an official RNS.
The big money's going to come from licensing fruitflow as an active ingredient in anything from fruit juice to baked beans.

We have tried both Sirco flavours and consider them to have an unpleasant aftertaste - wont buy them again at 2.19 a carton. Bought from Sainsburys in Southampton.

Provexis PLC
06 April 2006

PROVEXIS PLC
('Provexis' or the 'Company')

Trading Update

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, issues a trading update for the year ended 31
March 2006.

The Company's lead product Sirco(TM) was launched in Sainsbury's, Waitrose and
Tesco on 2 January 2006, 26 January 2006 and 4 February 2006 respectively.
Sales, operating costs and the cash position for the year ended 31 March 2006
are in line with expectations.

Sirco(TM) is the first heart health product to contain the patented
Fruitflow(TM) technology. Fruitflow(TM) works by reducing blood platelet
aggregation ('thinning the blood'), a significant contributing factor to a
thrombosis (internal blood clot) which can lead to heart attack or stroke.

Licensing talks are on-going with major food and beverage corporations regarding
the global licensing of the Fruitflow(TM) technology across different
application areas. As previously announced on the 9 March 2006, an independent
Expert Panel in the United States affirmed that Fruitflow(TM) was Generally
Recognised as Safe ('GRAS'). Together with the existing clearance in the EU,
this development paves the way for products containing Fruitflow(TM) to be
marketed across two principal target markets.

In addition to Fruitflow(TM), the Company continues to develop its product
pipeline with two other technology platforms which are intended to underpin new
product launches in 2007 and 2008. The first of these products will be a
functional beverage, containing a glucosinolate-enriched broccoli extract for
reducing the risk of specific types of cancer. The second product will be a
medical food, based on a patented extract from plantain fruit, designed to
extend remission time in patients with Crohn's Disease.


For further information please contact:

Provexis plc
Dr Stephen Franklin 020 8392 6631


Bell Pottinger Corporate & Financial
Emma Kent/Victoria Geoghegan 020 7861 3232








This information is provided by RNS
The company news service from the London Stock Exchange

i love both flavours.so does my wife and many of my friends,they taste much better than a STROKE would.some supermarkets are now giving it more shelf space..todays news remind's us what masive potential this share has,the sky's the limit..must top up my fridge and my share holding..

very difficult to release something like a reasonable trading statement when the product has only been in the shops for a few weeks. if i get the chance later i will phone the company and ask where this 2.5 million advertising budget is being/planned on being spent because i have seen nothing so far. (unless someone else calls them first). but, so far so good.

Morning. Have seen adverts in the Sunday times magazine a few times. Personally I do not like the name sirco, but if it sells who cares.

Just trying to think through likely volume. Starting from the outlets: say 1000 at avaerage 20 cartons stocked say one week's stock would be 1 million unit sales or arounf 32m. Starting from the user market: 3 million statin users should give 1 million consumers who should buy regularly; if 50 a year would give volume of 50 million p.a. or 100m sales. Wide discrepancy! But I reckon that msot people who start will become addicts whether they kile the flavour or not. I take a statin table plus an aspirin each day: if I were convinced that Sirco should replace the aspirin then I would take my drink religously wrong word: who does religion serriously?). Perhaps this rumination might start others off. I do suspect the cap. could quickly grow to the 100m area: what about the US market?

Eric

maybe the Sirco would also improve your typing/spelling....LOL

good luck everyone

GN

global nomad, eric's spelling is usually fine .......... unless he's been on the rioja ;)

nice little write up in shares mag in a feature about the uk healthy food market


"Functional foods company Provexis (PXS:AIM) also has high hopes
for the health drink it launched this year. The company joined AIM in
2005 through a reverse takeover of Nutrinnovator and has recently
begun selling its Sirco health drink, which contains a patented tomato
extract called Fruitflow.
The Fruitflow technology has been proven by scientists to help thin the
blood in the body, which can reduce the chances of forming potentially
dangerous blood clots. Sirco has been endorsed by HEART UK, a charity
which specialises in high cholesterol and cardiovascular disease.
When we approached retailers, they wanted a charitable
endorsement on the product and we had to present our evidence to
HEART UKs scientific panel, says CEO Dr Stephen Franklin, adding
that the approval has helped with the marketing campaign.
As the drink has only been on the market for a matter of months,
there are no sales figures yet but the initial reactions have been
promising. Arbuthnot analyst Robert Sanders has a target price of 15p
for the shares, 36% above their current 11p. However, the company is
also looking at global licensing deals for the Fruitflow technology as it
could be incorporated into any already existing drinks brand. Franklin says it is hoping to have some news about a potential deal within the
next six months and Sanders believes that a licensing deal would be a
huge catalyst for the shares pushing them well above the target price."

Thanks bos for posting that: why make the drink when someone else can add it under license. Its also a way of capturing additional m,arket and accessing the people whom it will really help. If 3 million in the UK then 30 million in the US and how many worldwide? Beginning to believe my calculation of a cap. of 100m and will build up my cfd position. By the way, bos, you can take out a cfd with blue index on PXS on a 4:1 margin.

OK glomad, as bos says, it was a particularly good red that night - will dig out the bottle if you want to know. Only had a coulple of glasses at the Golf Club, have checked my spelling and it is bolddlly acculate!

Eric

cheers eric,

wonder if fruitflow can be added to any drink, rioca perhaps. Isn't a little red wine good for you anyway?

and while we're at it what about food.

enjoy the w/e

GN

Provexis aims to push ahead with new health products Apr 7 2006




Daily Post


HEALTH and medical foods developer Provexis yesterday said its trading was in line with market expectations and said new products were in the pipeline.

The Liverpool-based company has enjoyed rapid progress in recent months, marketing its health juice drink, Sirco, which it claims can reduce the risk of a heart attack or stroke.

The drink is now available in hundreds of Sainsbury's, Waitrose and Tesco supermarkets in the UK and Provexis is aiming to expand its market to the United States.

In yesterday's statement it said: "The company continues to develop its product pipeline with two other technology platforms which are intended to underpin new product launches in 2007 and 2008.

"The first of these will be a functional beverage, containing a glucosinolate-enriched broccoli extract for reducing the risk of specific cancers. The second product will be a medical food, based on a patented extract from plantain fruit, designed to extend remission time in patients with Crohn's Disease."




http://iccheshireonline.icnetwork.co.uk/0100news/0200businessfarmingnews/tm_objectid=16915508&method=full&siteid=50061&headline=provexis-aims-to-push-ahead-with-new-health-products-name_page.html

I have been tracking back over various sites for information that might give any other leads for any agreements. Couldn't find anything particularly enlightening although this article from january about the issues of marketing products that deal with illness/death/ cancer etc. came up with the following that reminds us that Fruitflow is looking to be incorporated (licensed) into a variety of different product markets. Whether this means various licenses in different sectors or with a company that operates in various sectors........

"
However, trying to sell these products without harping on about diseases is difficult, admits Stephen Moon, commercial director of functional ingredients and foods group Provexis, which is about to launch its Sirco blood thinning drink and license its Fruitflow tomato extract (Sirco's active ingredient), to other manufacturers for use in JUICES, DAIRY PRODUCTS AND SNACKS.

"The technical side isn't hard," he says. "Fruitflow is robust and adaptable, water soluble and easy to mask; it can stand heat treatments and has a good shelf life in most products [six months]. The difficulty is getting the message across. It works by reducing the mechanism [platelet aggregation] responsible for blood clots. That's what kills you when you have a heart attack. But how do you talk to consumers about that?"

http://www.foodmanufacture.co.uk/news/fullstory.php/aid/2659/Don't_mention_the_c-word.html

GN

bit of bad news which should see the sp drop today. buying opportunity or is it time to get out ??

Provexis PLC
20 April 2006


PROVEXIS PLC
('Provexis' or the 'Company')

Change to current Sirco Listings

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that J Sainsbury will de-list SircoTM
from 17 May 2006.

In a quarterly range review, the retailer announced a wide-ranging
rationalisation of chilled juice brands, encompassing both established brands
and some newer products, including Sirco(TM).

This decision by J Sainsbury has no impact on our distribution agreements with
Tesco and Waitrose and Sirco(TM)continues to see an increasing rate of sale in
both the 550 Tesco stores and 120 Waitrose stores in which the product is sold.
Furthermore, the Company is in discussions with other major multiple and high
street retailers to extend distribution of the existing one litre product and
also the forthcoming 250ml single-serving pack.

Commenting on the news, Dr Stephen Franklin said:

'Naturally we are frustrated to lose a customer in the early stages of launch,
whilst we are establishing the brand with consumers via our national marketing
campaign. However, we understand that this decision has been made by J Sainsbury
as a result of the significant rationalisation of its juice category. Our
remaining customer base is extensive and we are increasing the rate of sale at
these stores. In addition, we are progressing discussions with other retailers
in order to increase our distribution within the multiple grocer and health
channels.'

Hi bosley,

I have been reading the much more extensive posting on iii though some of it seems to be more bickering than discussing.....

I have just bought a few more with the view that this is an over reaction and that the news also suggest sales are doing well in the other stores. It has also been noted that the licensing agreements are the key to success and that this product is to some extent only a proof of concept.

Results in a few weeks may hold the key for this longer term outlook/growth.

agreed global nomad. it does look like an over reaction but the news did spur the company to give an indication of how well sales are going in the other stores. i don't understand why they seem to be targeting the traditionally higher end supermarkets. what's wrong with asda/morrisons? surely they are not being snobbish? hopefully , the results will give some numbers rather than percentages. i hate percentages as they can be so misleading.

A minor hiccup. pxs has huge potential. Very short sighted of Sainsbury's to reject a potential 'brand name' product imho. It's not helped by the fact of being a single product company at the moment.

Nothing to say they won't re-instate in the future.

Patience.

jtf

If youve had a good day please consider giving a donation to the lads dressed as Elvis racing 350 miles to the North Pole on behalf of Great Ormond Street Hospital It makes the London Marathon seem like a stroll in the park!
To donate or view how theyre getting on visit
http://www.elvispolarchallenge.co.uk/
thanks for your time

Reckon Sainsbury is not significant in terms of the larger picture. Agree GlobNom (should that be lobGnome?) that this is really proof of concept for the larger licensing deals, particularly in US. Given its minor significance, lopping 1/6th off the sp makes little sense and gives a buying opportunity.

Eric

absolutely, stay on the rails GWR

Really surprised to see continual weakness given that the Sainsbury delisting was not that significant in the larger scenario: licensing deals; additional clients; US. Buying opportuntity.

Eric

Topped up today. It seems to me that the potential numbers from licensing deals could be way ahead of the cap. The current sp is one-third back from the peak following the announcement of the three super-market deals; suspect the Sainsbury setback is a mere hiccough. But my main argument is that we have not had an announcement for some time yet they are busy developing opportunities, particularly in the US. Such a deal must lead to a re-rating of the share.

Eric

I don't think the current price of PXS makes much sense. The drop on the Sainsbury news was on pretty low volume, signifantly less than a single day's trading in Novemeber and January. The price is approximately that before the news from the supermarkets but PXS has clearly made good progress since then with Sirco, US approval has been obtained and we also know now that talks are progressing re licensing the Fruitflow product for use with other drink which sounds potentially much more profitable than building up your own distribution business. My view is that the sp will return to around 10p, probably by the end of the month, and then take a significant jump when a licensing deal is done. I am in with a CFD so plan to accumulate as the sp rises.

Eric

I bought a small holding today... think the Nestle deal should be announced soon!
Also read in the metro yesterday that DVT is affecting computer users (so as long as PXS makes people aware that this helps blood thinning & circulation, think we have a potential BIG winner!)

some news today. does anyone else think that maybe the company is focusing too much on the science and less on sales?

Provexis PLC
16 May 2006


PROVEXIS PLC

('Provexis' or the 'Company')

SircoTM science to be published in leading scientific journal

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces a major international scientific
endorsement for its lead product SircoTM. Two scientific papers, which detail
the clinical efficacy of SircoTM, are to be published by the American Journal of
Clinical Nutrition (AJCN). The AJCN is internationally recognised as the
highest-ranked peer-reviewed journal in the nutrition field.

SircoTM, a chilled fruit juice, is the first heart health product to contain the
patented FruitflowTM technology. FruitflowTM is a natural bioactive extract from
tomato that works by reducing blood platelet aggregation within hours of
consumption. Platelet aggregation plays a significant role in the formation of a
thrombus (internal blood clot) which can cause a heart attack or stroke.

SircoTM is currently available in the UK in the chilled juice category in over
550 Tesco and Waitrose stores. The product is targeted at adults who are keen to
maintain cardiovascular health.

Commenting on the news of the acceptance by the journal, Dr Stephen Franklin,
CEO of Provexis, said:

'We are delighted that the science behind FruitflowTM has been accepted for
publication by the highest-ranked peer-reviewed scientific journal in the field.
We have remained resolute in our belief that the FruitflowTM technology is
world-class and that this would be recognised by the most stringent scientific
review process in the field of clinical nutrition.'

'The acceptance of two separate scientific papers, published in this
internationally accredited journal is a significant milestone for the Company
and an essential precursor to initiating a number of key commercial activities'.


For further information please contact:

Provexis plc

The science needs to be there to back up the claims especially when it comes to marketing - and not only to consumers but also to potential partners/licencees.

As far as I am concerned the more the better. we don't want this to come across as some b/s marketing or quack cure all.

The market is clearly split but many people who take care of themselves (or can afford to) are going to be educated enough to be curious about claims. A level of sceptisism about the credibility of some scientific claims and journals already exists but that is probably not an issue.

Various manufacturers in the past have had to withdraw products or marketing/ads when printed claims were found to be misleading and that seriously damages a products credibility. So ensuring that your claims can be substantiated is very important.

GN

gn , agreed. my point was that maybe the focus is on pleasing the scientists and not consumers. pxs have said that the problem they have found is in explaining to joe public the benefits of sirco without getting too scientific or gory. other companies have managed to find a way, actimel, benecol, mmmmmmm danone , etc. i'm sure if pxs started using some of that 2.5 million advertising budget they bragged about then maybe they too can find a way.

bos: I think you have misse the point that this is an American journal. Iexpect this is an essential point of the PXS marketing campaign with the objective of landing licensing deals. The scientists of companies like Nestle must the key players in landing such deals. Good to see the recovery from yesterday's fall on the back of this announcement.

Eric

nice day today for pxs. eric, i don't think i've missed the point. all i'm saying is that, when all is said and done, this is a product. the product has to sell. other companies have managed to get across the scientific message in their advertisements , so it can be done. it it would be a real pity if pxs used this difficulty in explaining the science to joe bloggs as an excuse for lacklustre sales. i mean, would sainsbury's have dropped it if it was flying off the shelves? i'm still holding .... i just don't understand why the company isn't advertising the product all over the tv!! that's all it needs.

Fair point, bos. My point though is that the real money will not be made from selling drinks through the UK supermarkets but from licensing the product which they are best doing in the US to get the volume; similar to the 'idea' of SEO and Greenseal but that might not be the best parallel! I think that is why the market has responded positively to the US Journal.

Eric

morning boys and girls....

What yesterdays sp performance showed us all was just how much this share will respond to news - whether we think the nature of yesterdays news was important or not. Clearly there are enough who think it marks a significant point - now imagine what will happen when a sales related news is issued ie a licencing agreement ..with a major company perhaps..

just thinking about all the actimel type drinks and how long they took to reach the point they are at now - certainly not in a few months - they have been around for several years and only really took off in a big way last year for all kinds of reasons..so brands do take time to build and it will happen...

GN

GlobNom Really perceptive post with which I fully agree. What is your view about possible value of a licensing deal: I would manage an up-front payment with an on-going royalty based on volume. If a deal were worth 10m then that would be effectively gross = nett and would justify an sp of double that present (on a one-off basis) or several times if repetetive. We could be dealing with some big numbers, which was the basis of my comment above to Bos.

Eric

Useful rise Friday with some buying although not alrge volumes. I expect to see a steady rise in anticipation of a licensing deal in the US.

Eric

results day .

Provexis PLC
15 June 2006



PROVEXIS plc
('Provexis' or the 'Group')

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 MARCH 2006

Provexis plc the nutraceutical company that develops scientifically-proven
functional and medical foods, announces its unaudited preliminary results for
the year ended 31 March 2006.

Financial Highlights

Results in-line with expectations

Sales of lead product SircoTM of 140,000 in first 3 months since launch

Total turnover of 268,000, decreased by 56 per cent. (2005: 609,000);
mainly due to the decrease of a one time non recurring fee paid by
Nutrinnovator Holdings to Provexis Limited in the prior year

Adjusted loss before interest, goodwill amortisation, share compensation
expense and tax of 2,528,000, increased by 320 per cent. (2005: 601,000)

Cash balance 2,166,000 (2005: 1,106,000)

Operational Highlights

Completion of reverse takeover of Nutrinnovator Holdings plc, placing
and admission of Provexis plc to trading on AIM

Lead product SircoTM launched in major UK supermarkets in January 2006
US patent granted for FruitflowTM technology

Product endorsement agreement with HEART UK for lead product SircoTM

Independent Expert Panel in United States affirmed that FruitflowTM
technology is Generally Recognised as Safe ('GRAS'), paving the way for
products containing FruitflowTM to be marketed in the North America

Collaboration agreement with leading global clinical nutrition company
for the development of Provexis' Crohn's disease technology

Awarded 180,000 research grant for Crohn's Disease Technology from
North West Development Agency

Post year-end achievements

International scientific endorsement for clinical efficacy of SircoTM
from the highest-ranked peer-reviewed journal in the nutrition field

Single serve 250ml bottle of SircoTM to be launched on schedule this
summer, initially in 150 Holland and Barratt stores with further
distribution in independent health food stores

Licence negotiations for FruitflowTM technology at an advanced stage
Secured a Standby Equity Distribution Agreement with a capital provider
for 3 million, to be utilised at our discretion


Dr Stephen Franklin, Chief Executive Officer of Provexis plc, commented:

'In line with our targets, we have succeeded in launching our lead product
SircoTM into major retailers in the UK. Furthermore, in the United States, our
FruitflowTM technology has secured a vital patent grant and has made a
significant advance towards its regulatory clearance. The FruitflowTM technology
has also received a major scientific endorsement by being accepted for
publication by the highest ranked peer reviewed journal in the nutrition field.

These achievements are major milestones in the development of the company and
unlock significant global commercial opportunities. Negotiations regarding the
licensing of the FruitflowTM technology are at an advanced stage and further
details will be announced in due course.

In addition to the progress made with our lead product SircoTM and the
FruitflowTM technology we have also continued development of our product
pipelines with two other technology platforms - a glucosinolate-enriched
broccoli extract to reduce the risk of specific types of cancer, and a patented
plantain based extract for the treatment of Crohn's Disease.

I am pleased with the progress that the Company has made since its admission to
AIM in June 2005 and believe that the Company is well-positioned to continue its
growth during the next 12 months and to capitalise on worldwide opportunities in
the rapidly growing functional food market.'

-ends-


For further information please contact:


Stephen Franklin, Chief Executive
Provexis plc Tel: 020 8392 6631

Victoria Geoghegan
Bell Pottinger Corporate & Financial Tel: 020 7861 3232

Tom Griffiths/Richard Dunn
Arbuthnot Securities Limited Tel: 020 7012 2000



Chairman's statement

The Company has made considerable progress in the year ended 31 March 2006.
Since the reverse takeover of Nutrinnovator Holdings plc, we have successfully
integrated the two businesses whilst remaining focussed on the delivery of
several major milestones. Provexis combines excellent scientific, marketing and
sales talent which enables us to develop and commercialise new functional food
technologies via a combination of licensing and new brands.

In 1998, Professor Asim Dutta-Roy made the discovery that the clear fraction of
tomatoes contained compounds that inhibited blood platelet aggregation, thereby
helping to maintain a smooth blood flow and as a result maintain a healthy heart
and circulation. After seven years of development, it has been extremely
rewarding during this period to witness the emergence of this technology in the
market place. The technology is now known as FruitflowTM, and the first product
to contain this bioactive is the fruit juice drink, SircoTM. SircoTM, endorsed
by the charity HEART UK, was launched on schedule in major UK supermarkets in
January 2006.

We are encouraged by the steady increase in the rate of sale of SircoTM and
favourable performance benchmarks against other functional fruit juices in the
market. In Tesco, we are encouraged by the fact that SircoTM now enjoys a rate
of sale which is comparable to many more established brands.

SircoTM has been strategically important to Provexis as a demonstrable example
of the FruitflowTM technology in action and there is little doubt that launch of
the brand in the UK has facilitated global licensing discussions with major food
and beverage companies. The Directors believe a successful licensing strategy,
across foods, supplements and medical products, is central to maximising the
value from the FruitflowTM technology and I am pleased with the advanced status
of these negotiations.

We recently received notice from the American Journal of Clinical Nutrition
('AJCN') that they have accepted for publication two scientific papers which
detail the clinical efficacy of SircoTM. The AJCN is internationally recognised
as the highest ranked peer-reviewed journal in the nutrition field and this
represents a major endorsement for the technology. This development is key to
implementing an effective and credible PR campaign and over the coming months
activity in this area will be escalated.

In conjunction with the University of Liverpool and Professor Jon Rhodes, the
Company continues to develop a medical food, based on a patented extract from
the plantain banana, for the dietary management of Crohn's disease, a condition
for which there is currently no cure. We also entered into a collaboration with
a global clinical nutrition company and secured a substantial research grant
from the North West Development Agency. The product enters clinical trials, on
schedule, this summer.

Provexis continues to work closely with Plant Bioscience Limited the
intellectual property arm of The Institute of Food Research in Norwich, to
develop a functional food product enriched in cancer-protective compounds
extracted from broccoli.

The functional food sector continues to grow strongly in all major markets
worldwide and I believe that Provexis, with its evidence-based approach, is
uniquely positioned to be a significant source of innovation for the industry.
We look forward to making yet further progress during the next year.


Dawson Buck
Chairman


Management review

The Provexis business model is to develop patented extracts from food which have
clinically proven health benefits. The intention is to commercialise these
technologies in the functional food and medical food markets via a combination
of new brand development and licensing to major brand-holding food and clinical
nutrition companies.

Year's highlights

During the year ended 31 March 2006 we have made considerable progress with our
technology pipeline and, importantly, have also integrated the two businesses
following the reverse takeover of Nutrinnovator last summer.

The launch of our lead product SircoTM in the UK, on schedule in January 2006,
represented an important milestone in the Company's progress. The SircoTM
trading business is significant in its own right, but the wider ambition for the
launch was to act as a catalyst for the global commercialisation of the
underpinning FruitflowTM technology. We have made very encouraging progress in
licensing negotiations, some of which are at an advanced stage, with major food
and beverage companies.

In addition to the successful development of our lead product, the Company also
secured a US patent for the FruitflowTM technology and subsequently an Expert
Panel in the United States affirmed that the ingredient was GRAS. These are two
critical developments in realising our licensing ambitions and enabling us to
penetrate our largest target market with FruitflowTM containing products. The US
functional food market is expected to reach US$34 billion of sales by 2010.

Financial Review

Total turnover for the Group for the year ended 31 March 2006 was 267,660.
Group turnover from continuing operations was 139,972 for the year ended 31
March 2006, arising from the sale of SircoTM. SircoTM was launched in three of
the UK's supermarket chains during the first quarter of 2006. Group turnover
from discontinued operations for the year ended 31 March 2006 was 127,688.

The turnover decrease from continuing operations of 55 per cent. for the year
ended 31 March 2006 compared to the year ended 31 March 2005 was principally due
to the one-off fee of 310,000 paid by Nutrinnovator Holdings plc to Provexis
Limited in the year ended 31 March 2005 partially offset by sales from the
launch of Sirco during the fourth quarter of fiscal 2006.

The turnover decrease from discontinued operations of 57 per cent. for the year
ended 31 March 2006 compared to the year ended 31 March 2005 is due to the sale
of the Altu food bar business on 4 October 2005.

Other administration expenses for the year ended 31 March 2006 were 2,940,992
compared to 1,441,158 for the year ended 31 March 2005. The increase was due to
increased overheads for the new group following the reverse acquisition in June
2005. In addition, exceptional re-organisation costs of 119,850 have been
charged to the profit and loss account.

Operating loss before interest and taxation from continuing operations for year
ended 31 March 2006 totalled 3,346,385 compared to an operating loss of
1,106,715. The increase in operating loss is mainly due to the decrease in
revenues for the year and the new group structure following the reverse
acquisition of Provexis Limited in June 2005. Share option compensation expense
of 455,446 was charged to the profit and loss account during the year in
connection with share options granted at exercise prices that were lower than
market price on the date of grant. Also, included in operating loss is
amortisation of goodwill arising from the reverse acquisition of Provexis
Limited in the amount of 363,264.

Operating loss before interest and taxation from discontinued operations for the
year ended 31 March 2006 totalled 172,003. The Altu food-bar business was sold
to Altu Limited, trading as Go Lower Limited in October 2005. A provision of
32,756 was recorded in September 2005 in connection with certain write-offs
following the sale of the Altu business.

Cash at bank as at 31 March 2006 was 2,166,243 compared to 1,105,689. To
strengthen liquidity and capital resources the Company has secured a Standby
Equity Distribution Agreement with a capital provider for 3 million. Under the
agreement the Company may, at its discretion and throughout its term, sell
Ordinary shares up to the amount of 3million.

SircoTM heart health juice

During the period the industrial scale manufacturing process for the FruitflowTM
ingredient was finalised and the Company has successfully developed and launched
SircoTM, the first heart health drink to contain the active ingredient.
FruitflowTM works by reducing blood platelet aggregation, a significant
contributing factor to a thrombosis (internal blood clot) which can cause heart
attack or stroke.

SircoTM was launched during January 2006 in Tesco, Sainsbury's and Waitrose.
Since the year end Sainsbury's has de-listed SircoTM as part of its wide ranging
rationalisation of chilled juice brands reducing the distribution base. However,
the product continues to be sold in 550 Tesco stores and 120 Waitrose stores,
and we are witnessing an increasing rate of sale in both. In particular, the
steady growth of rate of sale in Tesco is encouraging and is comparable to many
of the more established brands.

Licensing of FruitflowTM technology

The Company is implementing a global licensing strategy for the FruitflowTM
technology in different areas of application ranging from food and supplements
to medical categories.

Negotiations are at an advanced stage with global food companies and further
details will be announced in due course.

Altu food bar

During the period, we completed the disposal of the Altu food-bar business in
order to focus on the core business of developing and commercialising functional
foods.

New product development

The Company entered into a collaboration agreement with a global clinical
nutrition company in order to facilitate the development of a novel medical
food, based on a patented extract from plantain, for the dietary management of
Crohn's disease. Crohn's disease is a chronic, relapsing disease of the
intestine which affects 1 in a 1000 people in the UK. The disease is incurable
and management of the condition is currently restricted to various drug regimes
and surgery. Furthermore, the Company secured a 180,000 research grant, after a
competitive pitch, from the North West Development Agency.

We continue to work closely with the technology transfer organisation of The
Institute of Food Research to develop a bioactive ingredient, sourced from
broccoli, associated with a reduced risk of developing certain types of cancer.
We are currently reviewing the relative merits of launching a new brand in the
UK followed by a global licensing strategy, or alternatively moving straight to
licensing arrangements.

The Group is eighteen months into a three year technology acquisition agreement
with Plant Bioscience Limited who continue to access their global network of 35
research institutes to find further functional food opportunities.

Outlook

In summary, we have made good progress during the period and met the milestones
that we set out to achieve at the time of our admission to AIM. The prospects
for the next twelve months are very encouraging. Most recently we have secured
another vital endorsement from the most highly regarded peer-reviewed
publication in the field of nutrition, the AJCN. This represents a major
validation of the quality of the science behind FruitflowTM.

We are delighted to announce that the single-serve 250ml version of SircoTM will
be launched this summer, on schedule, in independent health food stores and an
initial distribution base of 150 Holland and Barrett stores. We remain in
ongoing discussions with a number of retailers regarding new listings for both
the existing 1 litre and the new 250ml format.

We are currently in a very important period for the business with regard to
securing the first licensing agreement for the FruitflowTM technology and
thereby validating our business model. We remain confident of securing the first
of these arrangements in the short-term and believe that the Company is well
positioned to take advantage of the increasing global demand for functional
foods.


Stephen Franklin
Chief Executive Officer


full link

So the reaction to the Prelims is a fall in sp. This despite a positive chairman's statement. Note in particular (last para.) the 'confidence in securing the first (licenseing agreement) in the short-term... Suspect that the short-termers are out with their small profits. How short is short-term? Three months? News at AGM if not before? The point about a licensing deal is that it will be more or less gross equals nett and should certainly be very significant in terms of the current market cap. Good time to buy / top up.

Eric

with thanks to Phylis Stein over on iii

shows some good signs for the improving penetration of the company...



Hi Stephen

I know you are busy but I would like to pass on some (negative) feedback I have picked up regarding the H&B launch. It may be an isolated instance but if not, then there is some work needed to be done to rectify the situation - and I hope you are already on the case.

The following came from a regular (if somewhat cynical) poster on the iii.co.uk bulletin board:
"I had a chat with the H&B manager who told me that it (Sirco one shot) had come in 'last Tuesday', totally unexpected, no warning, no marketing material with it, and no explanation of what it is or what it does or who its aimed at etc... The manager had never heard of it so was totally uninterested. She did explain that new lines normally come with full details of the product, its benefits etc and marketing material. So thats going to fly off the shelves, isnt it?"

The same poster also pointed this out: "Has anyone called Tesco to check the latest number of their stores actively stocking Sirco? Remember it was only 301 a few weeks ago, not the 550 claimed by PXS."

Now, I fully understand that you cannot even attempt to correct misinformation and misunderstandings on the part of every commentator, but I would like to point out that the share price is very important and not just to investors. If you consider the share drawdown arrangement then clearly every penny on the price is of major consequence when it comes to PXS needing to raise cash. Better communication with the broader market can only help and a steady stream of positive news is really the best way. Meanwhile, if you can shed some light on the above comments I would be grateful. As ever, I recognise the scale of the task of launching a new product but hope you can provide some re-assurance on this.
Many thanks
****

14 July 2006 20:33:08
Stephen Moon (stephen@stephenmoon.com)

Hi Will

Apologies for the delay in replying, I have had a day holiday, so switched the phone off for a while.

Regarding H&B we have provided their head office with a bespoke marketing package including a custom poster advert. The implementation in H&B can sometimes be a bit slower than a major multiple, but it does come right. We have an agent who will call on all the stores on a regular four week cycle, and that is underway. We have gone with a Tetrapak package, as not all health stores have coolers, and therefore this pack will give us the best long term distribution potential, especially as the aseptic format gives us 9 months's shelf-life.

As well as H&B we are starting to move into independents, and had signed five large wholesalers as of Monday last. Regarding Tesco, I can't remember if I have replied to you on this, as there have been a number of emails on the subject. The situation is crystal clear: I personally look at EPOS data collected over the till of every Tesco store every Wednesday - I can see every bar code swiped for every single pack of Sirco in every Tesco store by day. As well as Sirco, I look at all our competitors weekly. I can tell you categorically that last week we sold Sirco in 514 Tesco stores -this number has been consistent for a number of weeks. I was concerned that we had lost two strongly performing stores, so we immediately sent in merchandising staff to investigate and rectify - we are very focused on this important account. The discrepancy between 514 and the quoted 550 is because stores in Northern Ireland and some of the Scottish areas are difficult to manage within the Tesco system, but we are still pushing there.

I hope this allays some of your concern.

Best regards
Stephen

****

typical!!! i was stopped out last week . now this ......

PROVEXIS PLC

('Provexis' or the 'Company')

Exclusivity Agreement


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has entered into an exclusivity
agreement for a period of 12 months with a major global branded food business
('Partner'), who, for reasons of confidentiality, cannot be named, for the joint
development and use of its patented Fruitflow(TM)heart-health technology.
Fruitflow(TM)is a bioactive food ingredient that reduces blood platelet
aggregation, a significant contributing factor to thrombosis, which can cause
heart attack or stroke.

Under the terms of the agreement, Provexis and its Partner will develop a
second-generation concentrated format of the Fruitflow(TM)product. The new
format will increase its applicability across all food, beverage, supplement and
medical formats. During the 12 month exclusivity period, the companies intend to
ensure technical and economic targets for the new format are met, and to
negotiate a global licence and supply arrangement for the FruitflowTM
technology.

According to Leatherhead Food International the market for heart benefit foods
is worth $4bn globally.

The scope of the exclusivity agreement covers all food and beverage formats
globally, with some specific exemptions. Provexis retains the right to
commercialise the Fruitflow(TM)technology on a global basis in the areas of
fruit juice and juice drinks, products marketed for deep vein thrombosis (DVT),
dietary supplements and prescribed medical products.
Commenting on the signing of the exclusivity agreement, Dawson Buck, Chairman of
Provexis said:

'This is an important milestone for Provexis. This agreement with a major global
brand owner will accelerate the development of our second generation
Fruitflow(TM) technology. If all goes well, we expect to move to a long-term,
global licensing deal with our partner within 12 months. In addition, we will
have a new technology platform to facilitate entry into the substantial consumer
and medical categories that fall outside of the agreement, and to this end, we
continue discussions with further potential licence partners.'

and this .....

Provexis plc, the nutraceutical company that develops scientifically-proven
functional and medical foods, today announces that Dr Stephen Franklin is
stepping down with immediate effect from his role as Chief Executive Officer,
and will not be seeking re-election to the Board at the Company's forthcoming
Annual General Meeting. Dr Franklin will continue to work with the Company until
early 2007 as Acting Director of Research. In this capacity he will complement
the Company's research and development team progressing late phase development
of the Company's proprietary technologies. The Company announces that Stephen
Moon has been appointed as Chief Executive Officer with immediate effect.
Stephen Moon, formerly Commercial Director of Provexis, has been with the
Company since February 2003.

Stephen Moon has been central to the strategic development of the Company. He
has been responsible for identifying and implementing revenue generating
opportunities, in particular pursuing key licensing agreements, and was
instrumental in the successful launch of the Company's Sirco(TM)product, which
incorporates its patented Fruitflow(TM)technology, into the major UK
supermarkets, Tesco and Waitrose, in February 2006. Prior to joining Provexis,
Stephen worked as Strategy Planning and Worldwide Business Development Director
at GlaxoSmithKline's nutritional healthcare division and in manufacturing and
supply chain roles at BP, Dalgety and Quaker.

Dawson Buck, Chairman of Provexis plc said:

'The Board would like to thank Dr Stephen Franklin for his significant
contribution to the establishment and development of the Company, particularly
since the reverse takeover of Nutrinnovator in June 2005. In addition we are
pleased that he will continue to work with the Company in an advisory capacity.

'I am delighted that Stephen Moon has accepted the role of Chief Executive. He
is highly regarded in the global nutritional sector and his wealth of experience
and extensive knowledge of the Company will prove invaluable in the next stage
of Provexis' development.

'As stated at the preliminary results announcement, the Board is pleased with
the progress that the Company has made since its admission to AIM in June 2005.
We believe that the Company is well-positioned to continue its growth by
capitalising on global opportunities with potential licensing partners in the
rapidly growing functional and medical foods market.'

Now doubled my shares had some that i bought at 12p,sold the rest for a small profit before the drop.Very good news today.

ah bollox!! i knew this would happen once i was out.

Provexis PLC
31 July 2006


PROVEXIS PLC
('Provexis')

Sirco Distribution Gains


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has extended the distribution of
its Sirco(TM) heart health juice drink, securing 235 Morrisons outlets with
effect from 14 August 2006.

Sirco(TM) contains the patented Fruitflow(TM) bioactive food ingredient that
reduces blood platelet aggregation, a significant contributing factor to
thrombosis, which can cause heart attack or stroke.

Sirco(TM) is currently distributed in approximately 640 Tesco and Waitrose
supermarkets, and also in 150 Holland & Barratt health food stores, as well as a
number of independent health food wholesalers.

Commenting on the new distribution, Stephen Moon, CEO of Provexis said:

'Securing this important retailer sees us continue to extend distribution of our
patented, scientifically-proven Sirco(TM) product in line with our business
plan.'

Time to take notice of PXS and those patient investors who have continued to have faith in the product development.

Unnamed collaboration of last six months or so is today announced as Unilever.

are you still in Bosley?